Evidence map›Paper›PMID 40099515›Full record

ArticleDermatology reports2025

Calcipotriol as a daylight photodynamic therapy enhancer: a case-control study.

Benedetta Sonego, Enrico Zelin, Serena Bonin, Tommaso Pozzebon, Giulia Bazzacco, Andrea Corio, Marina Agozzino, Dante Raffaele Caro Caposiena, Iris Zalaudek, Nicola Di Meo

Abstract read
In one paragraph

Article in Dermatology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Benedetta SonegoDermatology Clinic, Maggiore Hospital, University of Trieste. benedetta.sonego@gmail.com.
Enrico ZelinInstitute of Dermatology, Santa Maria della Misericordia University Hospital, Udine. enrico.zelin@gmail.com.
Serena BoninDepartment of Medical Sciences, University of Trieste. sbonin@units.it.
Tommaso PozzebonDepartment of Medical, Surgical and Health Sciences, University of Trieste. tommaso.pozzebon@gmail.com.
Giulia BazzaccoDermatology Clinic, Maggiore Hospital, University of Trieste. giuliabazzacco@gmail.com.
Andrea CorioDermatology Clinic, Maggiore Hospital, University of Trieste. andrea.corio.fe@gmail.com.
Marina AgozzinoDermatology Clinic, Maggiore Hospital, University of Trieste. marinaagozzino@gmail.com.
Dante Raffaele Caro CaposienaDermatology Clinic, Maggiore Hospital, University of Trieste. dcaposiena@hotmail.com.
Iris ZalaudekDermatology Clinic, Maggiore Hospital, University of Trieste. izalaudek@units.it.
Nicola Di MeoDermatology Clinic, Maggiore Hospital, University of Trieste. nickdimeo@libero.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Actinic keratoses (AKs) are common skin lesions found on sun-exposed areas and are considered potential precursors to squamous cell carcinomas (SCCs). This observational case-control study evaluates the efficacy of combining traditional daylight photodynamic therapy (DL-PDT) with pre-treatment using 0.005% calcipotriol (CAL) ointment. Twenty immunocompetent male patients with grade I-II AKs on the scalp and/or face were randomized into two groups: the case group received a 14-day pre-treatment with CAL ointment before DL-PDT, while the control group used a moisturizing cream. Both groups underwent a series of three DL-PDT sessions. The study utilized the Actinic Keratosis Area Severity Index (AKASI) scoring system to measure the actinic damage at baseline, 3 months, and 6 months post-treatment. Results showed a significant reduction in AKASI scores in the CAL group compared to controls, indicating that CAL pretreatment enhances the efficacy of DL-PDT. This combination treatment was well tolerated, with minimal discomfort reported. The findings suggest that incorporating CAL into the treatment regimen can improve the clearance of AKs and potentially prevent their progression to SCCs.

Identifiers

PMID40099515
PMCPMC11956547

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.